Beyond the prescription pad: antidepressants emerge as a quieter answer to chronic pain

For two decades, the dominant answer to chronic pain in the United States and much of Europe has been a tablet marked with a controlled-substance warning. On 14 June 2026, a large systematic review published in a leading medical journal proposed a quieter alternative: a category of drugs most patients associate with the brain, not the back. Antidepressants and certain antipsychotics, the analysis found, performed as well as opioids for several common chronic-pain conditions — and in some cases, marginally better.

The finding lands in a system that has been told, repeatedly, to prescribe fewer opioids. Until now, the prescription pad has had little to replace them with. That vacuum is the story.

What the review actually says

The review pooled evidence from a large number of randomised controlled trials — the kind of study design clinicians weight most heavily — comparing oral opioids against classes of drugs originally developed for depression, anxiety, and sleep disorders. Across outcomes for pain relief, sleep, and physical function, the antidepressants and antipsychotics were generally non-inferior to opioids. For some conditions the review did not specify, the alternatives performed slightly better; in others, slightly worse. The picture, the authors wrote, is one of equivalence, not of a clean winner.

Two specifics matter. First, the comparison was head-to-head: not "drug versus placebo" but "opioid versus alternative". That is the design regulators and physicians say they need before changing practice. Second, the alternatives are not risk-free. Antidepressants carry their own side-effect profile, and antipsychotics in particular are associated with metabolic and cardiac concerns that require monitoring. The review does not present these drugs as benign — it presents them as, on the available evidence, a comparable option when weighed against the well-documented harms of long-term opioid use.

Why this is bigger than pharmacology

The opioid epidemic in North America killed tens of thousands of people a year at its peak and continues to claim lives at a lower, stubborn rate. The policy response has been to throttle supply: prescription monitoring programmes, dose limits, the closure of pill mills. Throttling works, but it leaves a clinical gap. A patient who arrived at a pain clinic in 2010 was often handed an opioid; a patient arriving in 2024 is often handed nothing at all, and told to try physical therapy, yoga, or cognitive behavioural therapy. Some of those patients need pharmacological relief. The review suggests there is a third path that has been hiding in plain sight: repurpose drugs that already exist, that are off-patent, and that prescribing physicians know how to manage.

That repurpose strategy is not new. Several antidepressants have been used for neuropathic pain for years; the novelty is the scale of the evidence base now assembled and the breadth of pain conditions covered. The review also includes antipsychotics — a class whose use for pain is more controversial and less familiar to general practitioners. Including them in the comparison signals that researchers are willing to ask uncomfortable questions about why certain drugs have been excluded from pain guidelines on grounds of cost or tradition rather than evidence.

The structural read is straightforward. Pharmaceutical innovation has thinned. The pipeline of genuinely new non-opioid pain drugs has produced few winners over the past decade. In a thinner pipeline, the rational move is to mine the drugs that already exist. Repurposing is unglamorous work — no blockbuster launch, no prime-time advertising — but it is where the marginal returns on research spending currently sit.

What the alternatives do not solve

The review is not a panacea, and the authors do not pretend otherwise. Three problems remain.

The first is adverse effects. Antidepressants and antipsychotics have their own harm profile. Switching a patient from chronic opioid use to chronic antidepressant use is, in many cases, a trade — not a substitution. The right trade for some patients, the wrong one for others. Prescribers will still need to individualise.

The second is access. Antidepressants are cheap and widely available in high-income countries; the same is not always true in lower-income settings where pain specialists are scarce and where opioid supply, for historical reasons, has been more tightly controlled anyway. A finding that reorders American and British prescribing culture has a longer diffusion path into the rest of the world.

The third is the question the review does not directly answer: which patients benefit, and by how much? Pooled averages obscure heterogeneity. A drug that performs "as well as an opioid on average" may help some patients dramatically and fail others entirely. The next round of research — and the next round of clinical guidelines — will need to disaggregate.

Stakes and the near term

For prescribers, the immediate practical question is whether to change first-line therapy for the conditions covered by the review. Guideline bodies in the United States, the United Kingdom, and the European Union will now face pressure to revisit recommendations that have, in many cases, run in the opposite direction for a generation. The review does not compel that revision — but it makes the case harder to ignore.

For patients, the stakes are personal. A person with chronic neuropathic pain who has been told to taper off opioids has, until now, had a short list of evidence-based options. That list is now longer. Whether it reaches the consulting room depends on how quickly the medical establishment updates its habits — and habits, in medicine, move slowly.

For the pharmaceutical industry, the implications are uncomfortable. There is no patent-protected blockbuster at the end of this road. The winners are generic manufacturers, public payers, and the patients themselves. The losers are the firms whose commercial models depend on a steady churn of new branded analgesics. The review is, in that sense, a small victory for evidence-based prescribing and a quiet rebuke to the marketing-led culture that helped create the opioid crisis in the first place.

A note on uncertainty: the sources do not specify the exact journal of publication, the precise number of trials included, or the funding source of the review. Those details will matter when clinicians and guideline bodies evaluate how much weight to give the headline finding. For now, the claim is that the evidence is strong enough to justify changing the conversation — not, yet, to justify changing every prescription.

This article maps a single study against two decades of prescribing culture. Monexus reports the finding and the structural frame; the clinical judgment belongs to prescribers and their patients.